Abivax SA (FR:ABVX) has released an update.
Abivax, a clinical-stage biotech firm, has disclosed its share capital and voting rights details, with a total of 63,276,925 shares and 70,548,417 exercisable voting rights as of July 31, 2024. This information is crucial for investors tracking the company’s governance and potential influence in decision-making processes. Abivax is actively developing treatments for chronic inflammatory diseases, with its lead candidate, obefazimod, in phase 3 trials for ulcerative colitis.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
